Medeon Biodesign (ROCO:6499) ROCE %: -37.63% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6499 Medeon Biodesign Inc ROCO:6499
73 GF Score
Price NT$75.30
GF Value NT$96.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medeon Biodesign ROCE %?

Medeon Biodesign ROCO:6499 +9.93% 73 ROCE % is -37.63% as of Jun. 2026. GuruFocus rates ROCO:6499 with a GF Score™ of 73/100 and a GF Value™ of NT$96.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medeon Biodesign's annualized ROCE % for the quarter that ended in Jun. 2026 was -37.63%.

Medeon Biodesign  (ROCO:6499) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medeon Biodesign ROCE % Related Terms

Medeon Biodesign ROCE % Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign ROCE % Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.01 -10.79 -38.45 -40.74 -43.65

Medeon Biodesign Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.45 -57.40 -41.53 -33.93 -37.63
ROCO:6499
73GF Score
Medeon Biodesign Inc ROCO:6499
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeon Biodesign ROCE % Calculation

Medeon Biodesign's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-716.011/( ( (1877.743 - 215.642) + (1779.793 - 160.957) )/ 2 )
=-716.011/( (1662.101+1618.836)/ 2 )
=-716.011/1640.4685
=-43.65 %

Medeon Biodesign's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=-549.9/( ( (1679.425 - 143.979) + (1551.305 - 164.177) )/ 2 )
=-549.9/( ( 1535.446 + 1387.128 )/ 2 )
=-549.9/1461.287
=-37.63 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -37.63% mean?
Medeon Biodesign (ROCO:6499) has a ROCE % of -37.63% as of Jun. 2026.
Is Medeon Biodesign's ROCE % too high?
Medeon Biodesign's current ROCE % is -37.63%. Overall, Medeon Biodesign has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's ROCE % compare to ISRG and BDX?
Medeon Biodesign's ROCE % of -37.63% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 3.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 3.25, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medeon Biodesign's current ROCE % is -37.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$96.61, compared to a current price of NT$75.30 — trading 22.1% below its estimated fair value. The current ROCE % is -37.63%. Medeon Biodesign's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current ROCE % is -37.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$75.30 is trading 22.1% below its estimated GF Value™ of NT$96.61. GuruFocus considers Medeon Biodesign to be Modestly Undervalued.

Key valuation signals for ROCO:6499:

  • ROCE %: -37.63%
  • GF Value™: NT$96.61 vs. price of NT$75.30 (22.1% below fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
73GF Score

Get the complete analysis for ROCO:6499

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$75.30
Price
NT$96.61
GF Value